- Home
- GOSS vs NNOX Comparison
GOSS vs NNOX Comparison
Compare GOSS & NNOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- NNOX
- Stock Information
- Founded
- GOSS 2015
- NNOX 2011
- Country
- GOSS United States
- NNOX Israel
- Employees
- GOSS N/A
- NNOX N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- NNOX Medical Electronics
- Sector
- GOSS Health Care
- NNOX Health Care
- Exchange
- GOSS Nasdaq
- NNOX Nasdaq
- Market Cap
- GOSS 347.8M
- NNOX 248.7M
- IPO Year
- GOSS 2019
- NNOX 2020
- Fundamental
- Price
- GOSS $2.47
- NNOX $3.85
- Analyst Decision
- GOSS Strong Buy
- NNOX Strong Buy
- Analyst Count
- GOSS 4
- NNOX 2
- Target Price
- GOSS $8.50
- NNOX $8.50
- AVG Volume (30 Days)
- GOSS 3.1M
- NNOX 1.3M
- Earning Date
- GOSS 08-05-2025
- NNOX 08-12-2025
- Dividend Yield
- GOSS N/A
- NNOX N/A
- EPS Growth
- GOSS N/A
- NNOX N/A
- EPS
- GOSS N/A
- NNOX N/A
- Revenue
- GOSS $40,237,000.00
- NNOX $11,886,000.00
- Revenue This Year
- GOSS N/A
- NNOX $24.12
- Revenue Next Year
- GOSS $30.65
- NNOX $160.56
- P/E Ratio
- GOSS N/A
- NNOX N/A
- Revenue Growth
- GOSS N/A
- NNOX 17.36
- 52 Week Low
- GOSS $0.66
- NNOX $3.75
- 52 Week High
- GOSS $2.65
- NNOX $11.00
- Technical
- Relative Strength Index (RSI)
- GOSS 68.08
- NNOX 32.78
- Support Level
- GOSS $2.38
- NNOX $3.88
- Resistance Level
- GOSS $2.65
- NNOX $4.16
- Average True Range (ATR)
- GOSS 0.15
- NNOX 0.19
- MACD
- GOSS 0.03
- NNOX -0.02
- Stochastic Oscillator
- GOSS 76.67
- NNOX 8.44
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About NNOX NANO-X IMAGING LTD
Nano X Imaging Ltd is engaged in the business of manufacturing medical imaging systems. It offers a Nanox System which is a combination of hardware and software. It develops a prototype of the Nanox.ARC, a medical imaging system incorporating its novel digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that will allow for the delivery of medical screening as a service. It has three business segments: Nanox.ARC division, the radiology services division and the AI solutions division. Key revenue is generated from Radiology Services.